Profile data is unavailable for this security.
About the company
Simcere Pharmaceutical Group Ltd is a company engaged in research and development, production and sales of drugs. The Company's main products are generic drugs, including Bicun used for central nervous system diseases, Jepaso and Jiebaili used for oncology, as well as Yingtaiqing used for autoimmune diseases. The Company also produces various drugs, including Endostar used for oncology. The Company is also involved in providing promotion services for third-party drugs sold by medical institutions. The Company mainly conducts its businesses in the domestic market and overseas markets.
- Revenue in HKD (TTM)6.96bn
- Net income in HKD-1.21bn
- Incorporated2015
- Employees6.41k
- LocationSimcere Pharmaceutical Group LtdNo. 699-18, Xuanwu Road, Xuanwu DistrictNANJING ChinaCHN
- Websitehttp://www.simcere.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cansino Biologics Inc | 668.99m | -951.24m | 10.69bn | 1.49k | -- | 1.16 | -- | 15.97 | -3.85 | -3.85 | 2.71 | 22.48 | 0.0676 | 1.28 | 0.8385 | 447,782.40 | -10.15 | -4.27 | -13.73 | -5.60 | 14.38 | -- | -150.19 | -27.72 | 2.19 | -- | 0.3028 | -- | -66.52 | 213.94 | -63.04 | -- | 30.60 | -- |
| Luye Pharma Group Ltd | 6.93bn | 845.64m | 12.30bn | 5.23k | 14.55 | 0.8608 | 7.23 | 1.78 | 0.2248 | 0.2248 | 1.84 | 3.80 | 0.236 | 2.44 | 3.02 | 1,314,909.00 | 3.11 | 2.80 | 5.47 | 4.45 | 68.73 | 70.53 | 13.18 | 10.39 | 1.20 | 3.14 | 0.4103 | 11.82 | 2.70 | 3.50 | -11.94 | -16.39 | -14.05 | -- |
| Shanghai Henlius Biotech Inc | 6.19bn | 759.89m | 12.36bn | 3.55k | 16.31 | 4.37 | 10.61 | 2.00 | 1.39 | 1.39 | 11.34 | 5.21 | 0.5764 | 1.90 | 6.82 | 1,702,200.00 | 7.07 | -8.59 | 14.25 | -14.14 | 73.23 | 71.77 | 12.27 | -27.37 | 0.329 | 7.60 | 0.6113 | -- | 67.82 | 273.51 | 178.53 | -- | 49.14 | -- |
| SSY Group Ltd | 6.47bn | 1.37bn | 12.42bn | 5.80k | 9.14 | 1.72 | 6.79 | 1.92 | 0.4593 | 0.4593 | 2.18 | 2.44 | 0.5418 | 2.75 | 3.07 | 1,155,141.00 | 11.54 | 10.51 | 14.88 | 14.03 | 54.39 | 58.72 | 21.30 | 18.62 | 2.06 | 28.65 | 0.323 | 38.56 | 0.4505 | 9.10 | 17.44 | 7.66 | 3.94 | 13.56 |
| 3SBio Inc | 9.24bn | 1.82bn | 16.31bn | 5.61k | 9.11 | 1.03 | 7.22 | 1.76 | 0.7473 | 0.7473 | 3.79 | 6.59 | 0.3575 | 1.52 | 6.87 | 1,708,233.00 | 7.25 | 7.44 | 10.26 | 9.29 | 85.94 | 82.91 | 20.27 | 21.50 | 1.57 | 141.55 | 0.1998 | -- | 13.84 | 11.26 | -19.13 | 3.94 | 8.78 | -- |
| Simcere Pharmaceutical Group Ltd | 6.96bn | -1.21bn | 16.68bn | 6.41k | -- | 2.21 | -- | 2.40 | -0.4626 | -0.4626 | 2.70 | 2.98 | 0.5198 | 2.19 | 2.64 | 990,578.20 | -9.04 | 10.17 | -11.71 | 15.60 | 77.02 | 78.82 | -17.40 | 17.50 | 1.88 | 0.4721 | 0.1461 | 46.68 | 4.49 | 7.92 | -23.22 | -0.5213 | 23.93 | -- |
| Grand Pharmaceutical Group Ltd | 10.59bn | 2.41bn | 17.82bn | 10.78k | 7.29 | 1.13 | 6.20 | 1.68 | 0.6885 | 0.6885 | 3.03 | 4.43 | 0.4472 | 3.62 | 4.54 | 1,005,064.00 | 10.25 | 10.09 | 14.21 | 14.01 | 59.00 | 61.97 | 22.92 | 22.35 | 1.09 | -- | 0.2232 | 26.94 | 10.12 | 12.06 | -9.59 | 21.41 | 5.69 | 24.77 |
| Zai Lab Ltd | 2.51bn | -2.32bn | 18.99bn | 2.18k | -- | 3.42 | -- | 7.57 | -2.39 | -2.39 | 2.58 | 5.58 | 0.3083 | 3.04 | 5.52 | -- | -28.50 | -37.72 | -34.92 | -42.72 | 63.17 | 64.75 | -92.44 | -282.44 | 3.29 | -- | 0.0908 | -- | 24.03 | 360.03 | 24.51 | -- | -3.45 | -- |
| The United Laboratories Intl. Hldgs Ltd. | 15.38bn | 3.19bn | 19.91bn | 15.00k | 6.24 | 1.34 | 5.22 | 1.30 | 1.76 | 1.76 | 8.46 | 8.17 | 0.6578 | 3.30 | 5.67 | 1,025,069.00 | 13.65 | 7.89 | 20.72 | 12.64 | 46.15 | 44.17 | 20.75 | 12.73 | 1.72 | -- | 0.1532 | 28.99 | 21.22 | 12.84 | 70.85 | 31.66 | 24.19 | 46.04 |
| China Traditional Chinese Med Hldg CoLtd | 18.88bn | 1.01bn | 22.11bn | 17.72k | 21.95 | 0.9425 | 9.63 | 1.17 | 0.20 | 0.20 | 3.75 | 4.66 | 0.453 | 1.54 | 1.82 | 1,091,315.00 | 2.62 | 4.60 | 4.01 | 7.07 | 49.86 | 57.07 | 5.77 | 9.77 | 1.51 | 7.39 | 0.1808 | 17.35 | 26.69 | 9.99 | 68.11 | -2.24 | -12.75 | -- |
| China Medical System Holdings Ltd | 7.70bn | 1.53bn | 22.20bn | 5.78k | 14.57 | 1.26 | 12.55 | 2.88 | 0.6246 | 0.6246 | 3.15 | 7.23 | 0.384 | 2.89 | 5.65 | 1,350,396.00 | 7.51 | 18.44 | 8.53 | 21.14 | 74.13 | 75.47 | 19.56 | 34.26 | 3.97 | -- | 0.0667 | 40.14 | -12.43 | 8.08 | -26.33 | 5.35 | 38.69 | 5.19 |
Data as of Oct 10 2024. Currency figures normalised to Simcere Pharmaceutical Group Ltd's reporting currency: Hong Kong Dollar HKD
5.47%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Norges Bank Investment Managementas of 31 Dec 2023 | 24.51m | 0.96% |
| The Vanguard Group, Inc.as of 04 Jul 2024 | 18.01m | 0.71% |
| Fullgoal Fund Management Co., Ltd.as of 31 Dec 2023 | 16.71m | 0.66% |
| Bosera Asset Management Co., Ltd.as of 31 Dec 2023 | 14.91m | 0.59% |
| GF Fund Management Co., Ltd.as of 31 Dec 2023 | 13.73m | 0.54% |
| China Asset Management Co., Ltd.as of 31 Dec 2023 | 12.34m | 0.49% |
| Dimensional Fund Advisors LPas of 04 Jul 2024 | 11.66m | 0.46% |
| Essence Fund Co., Ltd.as of 31 Dec 2023 | 11.25m | 0.44% |
| BlackRock Fund Advisorsas of 04 Jul 2024 | 8.27m | 0.33% |
| HSBC Jintrust Fund Management Co. Ltd.as of 31 Dec 2023 | 7.82m | 0.31% |
More ▼
Data from 31 Dec 2023 - 06 Aug 2024Source: FactSet Research Systems Inc.
